Meda Pharmaceuticals

Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU
Telephone: 0845 460 0000
Fax: 0845 460 0002
Medical Information Direct Line: +44 (0)1748 828 810
Medical Information e-mail: meda@professionalinformation.co.uk
Medical Information Fax: +44 (0)1748 828 801
Out of Hours contact: +44 (0)1748 828 810

Summary of Product Characteristics last updated on the eMC: 21/01/2011
SPC Zidoval

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/01/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 07/07/2010 and displayed until 21/01/2011
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Updated on 21/09/2009 and displayed until 07/07/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Updated on 21/07/2008 and displayed until 21/09/2009
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 13/03/2008 and displayed until 21/07/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Updated on 14/08/2001 and displayed until 13/03/2008
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 12/07/2001 and displayed until 14/08/2001
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 11/07/2001 and displayed until 12/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 20/06/2000 and displayed until 11/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 20/06/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   metronidazole